Stoke Therapeutics, Inc. balance sheet STOK

Annual Quarterly

As of Sep 30, 2026, Stoke Therapeutics, Inc. had total assets of $406.7 million and total liabilities of $54.1 million. Total assets were up 12.9% from a year earlier. Stockholders' equity was $352.6 million. It held $358.8 million in cash and investments against $1.9 million of total debt, net cash of $356.9 million. The current ratio, current assets divided by current liabilities, was 7.24.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

FY 2026
Sep 30, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
FY 2019
Dec 31, 2019
Assets
Cash
107
+28.6%
84
-34.2%
128
-33.1%
191
+68.6%
114
-21.6%
145
-49.6%
287
+29.1%
222
Short-term investments
212
+28.5%
200
+125.4%
89
+793.4%
10
-91.4%
116
+54.9%
75
—
—
Long-term investments
40
-50.7%
106
+256.3%
30
—
—
—
—
—
Cash and investments
359
+9.2%
391
+58.4%
247
+22.5%
201
-12.3%
230
+4.5%
220
-23.5%
287
+29.1%
222
Receivables
9
-7.6%
6
—
—
—
—
—
—
Total current assets
354
+30.1%
306
+31.3%
233
+8.1%
215
-11.8%
244
+6.5%
229
-22.0%
294
+30.0%
226
Property and equipment, net
8
+166.4%
3
-19.5%
4
-32.9%
6
-12.8%
7
+61.3%
4
+54.7%
3
+6.5%
3
Total assets
407
+12.9%
418
+54.1%
272
+18.9%
228
-10.8%
256
+7.2%
239
-19.8%
298
+30.2%
229
Liabilities and equity
Accounts payable
4
-31.4%
5
+97.7%
2
+47.4%
2
+121.3%
1
-67.9%
2
+59.5%
1
+99.1%
1
Total current liabilities
49
+17.4%
58
+44.5%
40
+30.0%
31
-1.8%
31
+83.2%
17
+50.0%
11
+178.6%
4
Total liabilities
54
+3.7%
66
+55.1%
43
-38.2%
69
-3.4%
71
+237.7%
21
+78.0%
12
+174.1%
4
Stockholders' equity
353
+14.4%
352
+53.9%
229
+43.5%
160
-13.7%
185
-15.1%
218
-23.9%
286
+27.5%
224
Debt
Lease liabilities
2
-59.8%
4
-13.1%
5
-30.2%
7
+34.7%
5
-27.2%
7
+508.6%
1
—
Total debt
2
-59.8%
4
-13.1%
5
-30.2%
7
+34.7%
5
-27.2%
7
+508.6%
1
—
Net cash
357
+10.2%
387
+59.9%
242
+24.4%
195
-13.3%
225
+5.5%
213
-25.6%
286
—
Ratios
Current ratio
7.24x
5.28x
5.81x
6.99x
7.77x
13.37x
25.73x
55.12x
Debt to equity
0.01x
0.01x
0.02x
0.04x
0.03x
0.03x
0.00x
—
Return on equity
-68.98%
-1.95%
-38.85%
-65.62%
-54.68%
-39.40%
-18.26%
-14.40%
Return on assets
-59.80%
-1.65%
-32.77%
-45.85%
-39.47%
-35.92%
-17.54%
-14.13%
Book value per share
5.44
5.98
4.24
3.47
4.69
5.90
7.82
6.83
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
STOK (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Bedford, MA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1623526
Former names
ASOthera Pharmaceuticals, Inc. (until Nov 24, 2014)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.